STOCK TITAN

Point72 discloses 5.2% Precigen (PGEN) stake in Schedule 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Point72 Asset Management and related entities have reported a significant passive stake in Precigen, Inc. common stock. As of the close of business on January 22, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen jointly report beneficial ownership of 18,383,242 shares of Precigen common stock, representing 5.2% of the class.

The stake is held through Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. The reported amount includes 97,500 shares issuable upon exercise of call options. All three reporting persons share voting and dispositive power over the same 18,383,242 shares and certify that the securities were not acquired for the purpose of changing or influencing control of Precigen.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 97,500 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of call options.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 97,500 shares of Common Stock issuable upon exercise of call options.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 97,500 shares of Common Stock issuable upon exercise of call options.


SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:01/23/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:01/23/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:01/23/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What percentage of Precigen (PGEN) does Point72 report owning in this Schedule 13G?

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen report beneficial ownership of 5.2% of Precigen's common stock as of January 22, 2026.

How many Precigen (PGEN) shares does Point72 beneficially own according to the filing?

The reporting persons disclose beneficial ownership of 18,383,242 shares of Precigen common stock, including shares underlying certain options.

Does the Point72 Precigen (PGEN) stake include options or only common shares?

The reported 18,383,242 shares include 97,500 shares of common stock issuable upon exercise of call options tied to Precigen.

Who are the reporting persons in this Precigen (PGEN) Schedule 13G?

The filing is made jointly by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, pursuant to a Joint Filing Agreement.

Which entity actually holds the Precigen (PGEN) shares reported by Point72?

The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, which maintains investment and voting power under an investment management agreement.

Is the Point72 position in Precigen (PGEN) reported as passive or for control purposes?

The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Precigen, consistent with a passive Schedule 13G filing.

What voting and dispositive powers do the Point72 entities report over Precigen (PGEN) shares?

Each reporting person discloses 0 sole voting and dispositive power and 18,383,242 shares of shared voting and shared dispositive power over Precigen common stock.

Precigen Inc

NASDAQ:PGEN

PGEN Rankings

PGEN Latest News

PGEN Latest SEC Filings

PGEN Stock Data

1.71B
305.62M
10.47%
66.81%
12.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN